Clinical trial
Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)
NCT02380274
Study timeline
Study start (actual)2015-03-27Date precision: day
Registry last updated2024-11-20
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostate Cancerunresolved
Castration-resistant Prostate Cancerunresolved
Metastatic Prostate Cancerunresolved
Interventions
Sponsors & collaborators
Astellas Pharma Global Development, Inc.lead sponsor
Pfizercollaborator
Mapped research locations
NashvilleTennessee, United States3San DiegoCalifornia, United States2Oklahoma CityOklahoma, United States2OmahaNebraska, United States2RichmondVirginia, United States2TucsonArizona, United States2Winston-SalemNorth Carolina, United States2New OrleansLouisiana, United States2WichitaKansas, United States2WorcesterMassachusetts, United States2BillingsMontana, United States2ChicagoIllinois, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02380274 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.